CTXR

Citius Pharmaceuticals (CTXR)

Citius Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CTXR

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/29	21 : 30	PR Newswire (US)	Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/05/22	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/05/21	20 : 00	PR Newswire (US)	Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/05/15	05 : 26	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/05/15	05 : 05	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/05/15	05 : 05	PR Newswire (US)	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/05/10	21 : 30	PR Newswire (US)	Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/05/01	05 : 05	PR Newswire (US)	Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/04/26	21 : 00	PR Newswire (US)	Citius Pharmaceuticals Announces $15 Million Registered Direct Offering	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/04/11	21 : 30	PR Newswire (US)	Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/04/04	21 : 30	PR Newswire (US)	Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/03/18	21 : 30	PR Newswire (US)	Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/03/07	22 : 30	PR Newswire (US)	Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/03/04	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/02/26	21 : 30	PR Newswire (US)	Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/02/24	06 : 23	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/02/24	06 : 18	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/02/23	22 : 30	PR Newswire (US)	Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/02/15	22 : 45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/02/15	06 : 40	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/02/15	06 : 30	PR Newswire (US)	Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/02/14	23 : 18	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/02/14	22 : 01	PR Newswire (US)	Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/01/27	06 : 15	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/01/27	06 : 08	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/01/27	06 : 05	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/01/24	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/01/23	22 : 30	PR Newswire (US)	Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/01/06	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CTXR	Citius Pharmaceuticals Inc
2024/01/03	06 : 04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CTXR	Citius Pharmaceuticals Inc